Chronic Morbidity Among Older Children and Adolescents at Diagnosis of HIV Infection. by McHugh, Grace et al.
McHugh, G; Rylance, J; Mujuru, H; Nathoo, K; Chonzi, P; Dauya,
E; Bandason, T; Simms, V; Kranzer, K; Ferrand, RA (2016) Chronic
morbidity among older children and adolescents at diagnosis of HIV
infection. Journal of acquired immune deficiency syndromes (1999).
ISSN 1525-4135 DOI: 10.1097/QAI.0000000000001073
Downloaded from: http://researchonline.lshtm.ac.uk/2666000/
DOI: 10.1097/QAI.0000000000001073
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
CLINICAL SCIENCE
Chronic Morbidity Among Older Children and
Adolescents at Diagnosis of HIV Infection
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Hilda Mujuru, MBChB, MMed (Paeds), MSc Clin Epi,‡
Kusum Nathoo, MBChB (Birm), MRCP (UK), DCH (SA), MSc Clin Epi (Aus),‡
Prosper Chonzi, MBChB, MPH, MBA,§ Ethel Dauya, Dip. Nursing Studies, BA,*
Tsitsi Bandason, BSc Statistics, MSc Clin Epi,* Victoria Simms, MSc, PhD,k
Katharina Kranzer, FRCPath, MRCP, MBBS, MSc, PhD,k¶ and
Rashida A. Ferrand, MD, MSc, PhD*k
Background: Substantial numbers of children with HIV present to
health care services in older childhood and adolescence, previously
undiagnosed. These “slow-progressors” may experience consider-
able chronic ill health, which is not well characterized. We
investigated the prevalence of chronic morbidity among children
aged 6–15 years at diagnosis of HIV infection.
Methods: A cross-sectional study was performed at 7 primary care
clinics in Harare, Zimbabwe. Children aged 6–15 years who tested
HIV positive following provider-initiated HIV testing and counseling
were recruited. A detailed clinical history and standardized clinical
examination was undertaken. The association between chronic disease
and CD4 count was investigated using multivariate logistic regression.
Results: Of the 385 participants recruited [52% female, median age
11 years (interquartile range 8–13)], 95% were perinatally HIV
infected. The median CD4 count was 375 (interquartile range 215–
599) cells per cubic millimeter. Although 78% had previous contact
with health care services, HIV testing had not been performed. There
was a high burden of chronic morbidity: 23% were stunted, 21% had
pubertal delay, 25% had chronic skin disease, 54% had a chronic cough
of more than 1 month-duration, 28% had abnormal lung function, and
12% reported hearing impairment. There was no association between
CD4 count of ,500 cells per cubic millimeter or ,350 cells per cubic
millimeter with WHO stage or these chronic conditions.
Conclusions: In children with slow-progressing HIV, there is
a substantial burden of chronic morbidity even when CD4 count is
relatively preserved. Timely HIV testing and prompt antiretroviral
therapy initiation are urgently needed to prevent development of
chronic complications.
Key Words: HIV, Africa, adolescence, slow-progressors, chronic
lung disease
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BACKGROUND
Untreated vertically acquired HIV infection is associ-
ated with high mortality rates with a 50% probability of
dying by 2 years of age among African cohorts in the pre–
antiretroviral therapy (ART) era.1 However, as HIV epi-
demics have matured, survival estimates have been succes-
sively revised upward, and a substantial number of
perinatally infected children are presenting with HIV
infection in later childhood or adolescence.2–4 It is estimated
that a third of HIV-infected infants have slow-progressing
disease with a median survival of at least 16 years.5 Unlike
children who have rapid disease progression and present
with AIDS-deﬁning illness in infancy, children with slow-
progressing HIV are either paucisymptomatic or typically
have a history of multiple, nonspeciﬁc complaints, including
recurrent upper respiratory tract or skin infections that are
also common among their HIV-uninfected peers.6,7 Recog-
nition of HIV is consequently often delayed until pre-
sentation with advanced disease.6
There is strong evidence that immediate initiation of
ART reduces mortality in infants, in particular those under 1
year of age.1 The WHO 2013 HIV treatment guidelines
recommend immediate ART initiation on diagnosis regard-
less of clinical or immune stage in all children aged under 5
years.8 Such a beneﬁt has not been demonstrated for older
children.9 For those over 5 years, WHO 2013 guidelines
(which were standard of care when this study was being
conducted) recommended that, as for adults, ART is
deferred until the clinical stage 3 or 4 HIV disease is
apparent or if the CD4 count drops below 500 cells per
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millimeter.8 In 2015, the WHO further revised HIV treat-
ment guidelines recommending that ART be commenced in
all age groups regardless of clinical or immune status,
although evidence for immediate ART commencement is
lacking in older children and adolescents.10
While the risk of AIDS-deﬁning infections is low above
a CD4 threshold of 500 cells per cubic millimeter, long-standing
infection is associated with development of chronic complica-
tions, which may not fulﬁll the criteria for ART initiation.11 For
example, we have previously demonstrated a high prevalence of
chronic respiratory symptoms among adolescents with vertically
acquired HIV infection. However, objective measures of lung
function were not performed, and the study included both ART-
naive and ART-treated individuals.12
We investigated the prevalence of chronic symptoms,
including a standardized assessment of growth and lung
function and whether these were associated with immuno-
logical status among children aged 6–15 years at HIV
diagnosis of HIV infection.
METHODS
Study Setting
A cross-sectional study was performed in 7 public sector
primary health care clinics (PHCs) in 7 high population density
suburbs in southwest Harare, Zimbabwe between January 2013
and December 2014. Each suburb in Harare is served by one
main PHC, termed polyclinic, which provides acute primary
care, antenatal and postnatal care, mother and child health
services, HIV testing and care. Primary health care provision is
nurse led, supported by weekly consultation visits by a general
medical practitioner. Children are managed using WHO
Integrated Management of Childhood Illness protocols with
referral to the local hospital where required.13
ART and cotrimoxazole prophylaxis are provided free
of charge, although each HIV consultation visit incurs a cost
of US $1. Provider-initiated HIV testing and counseling
(PITC) ie, offering HIV testing to all individuals attending
health facilities regardless of the reason for presentation has
been part of WHO and Zimbabwean national guidelines since
2007 and testing is free of charge.14,15 Nurse-led ART
initiation for children was introduced at the 7 PHCs with
supervision from a physician (clinics having previously only
provided ART for those having been initiated on treatment in
secondary health care facilities). Nurses were trained on HIV
counseling and management, and ART was provided accord-
ing to national guidelines. Until February 2014, participants
were initiated on ART if their CD4 was below 350 cells per
cubic millimeter or had WHO stage 3 or 4 infection. From
March 2014, Zimbabwe adopted the WHO 2013 consolidated
guidelines, with the threshold for ART initiation revised to
500 cells per millimeter.8 All children were commenced on
cotrimoxazole prophylaxis at diagnosis of HIV infection.
Children aged between 6 and 15 years who tested HIV
positive at the study PHCs were offered enrollment into the
study. Children were excluded from the study if they resided
outside Harare, as follow-up may have been difﬁcult due to
distance to travel to attend clinical review.
Clinical Assessment
Clinical history was recorded using an interviewer-
administered questionnaire. Contact with health services,
history of past illness, exposure to ART including maternal
ART for prevention of mother-to-child HIV transmission
(PMTCT), drug history, and acute and chronic symptoms
were recorded, including respiratory and gastrointestinal
symptoms, and problems with hearing, vision, speech, and
gross motor function. HIV infection was staged using the
WHO Staging System and a CD4 count.16
A standardized physical examination was performed,
including inspection of the skin for herpes zoster scarring,
papular pruritic eruptions, planar warts, verrucous warts,
molluscum contagiosum, fungal infection, and Kaposi sar-
coma. The oral cavity was examined for gingivitis, perio-
dontitis, candidiasis, and Kaposi sarcoma. Anthropometric
examination included measurement of height and weight. The
head circumference was determined by measuring the greatest
occipitofrontal circumference, with the larger of 2 readings
recorded. Tanner pubertal staging was performed in children
aged .9 years.17 In females, breast and pubic hair develop-
ment and age at menarche were recorded. In males, testicular
volume, measured using an orchidometer, pubic hair devel-
opment, and penile length were assessed.
Cardiorespiratory function was assessed by the Medical
Research Council Dyspnea Scale Score and modiﬁed incremen-
tal shuttle walk test (ISWT) with pretest and posttest recording of
respiratory rate, heart rate, and peripheral oxygen saturations.18,19
ISWT was not performed if baseline oxygen saturation was less
than 88%, or if resting heart rate or respiratory rate exceeded 120
and 30 per minute, respectively. Spirometry was performed by
trained nurses using an EasyOne World spirometer (NDD
Medical Technologies Inc., Andover, MA). After demonstration
of the procedure, the participant performed forced exhalation
maneuvers while seated until quality criteria had been reached or
8 trials had been completed. The trial with the highest forced
expiratory volume at 1 second (FEV1) and forced vital capacity
(FVC) was selected for interpretation. Reversibility testing by
repeat spirometry was performed 15 minutes after administration
of 2.5 mg of nebulized salbutamol, if any abnormality ie, either
obstruction as deﬁned by FEV1:FVC of less than 1.64 SD below
the mean or restriction as deﬁned by FVC ,1.64 SD below
mean with normal FEV1:FVC ratio, was present.20
Laboratory Investigations
CD4 count was measured using an Alere PIMA CD4
(Waltham, MA) machine. Full blood count, renal, and liver
function tests are not a prerequisite for starting ART in
national guidelines, and these were only performed if
clinically indicated. Participants who screened positive on
the WHO TB screen were asked for a sputum sample.21
Sputum was examined onsite by Ziehl-Nielsen smear micros-
copy and Xpert TB (Cepheid, Sunnyvale, CA).
Data Management and Analysis
Data were collected from paper forms by optical mark
recognition (Cardiff TELEFORM Intelligent Character,
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version 10.7) and analyzed using STATA, version 12.1
(STATA Corporation, College Station, TX)). Z-scores for
height-for-age, weight-for-age, and head circumference–for-
age were calculated using the 1990 British growth reference
curves.22 Spirometric indices were expressed as z-scores
using GLI2012 reference ranges.23 The association between
a priori deﬁned variables and CD4 count was determined
using logistic regression, adjusting for age and sex. Missing
variables were excluded in logistic regression analysis.
Clinical Definitions
A z-score of ,22 for height-for-age and weight-for-
age was considered to represent stunting and wasting,
respectively. Pubertal delay was deﬁned as girls not having
reached Tanner 2 breast development by age 12 years and
boys not having reached Tanner 2 testicular volume by age 14
years.24 An obstructive lung defect was deﬁned as FEV1 less
than 1.64 SDs below the mean and FEV1:FVC of less than
1.64 SD below the mean. A reduced FVC (which would be
suggestive of restrictive defect) was deﬁned as an FVC below
1.64 SD below the mean with a normal or increased FEV1:
FVC ratio.23 Reversibility of either obstructive or restrictive
defect was deﬁned as greater than or equal to 12%
improvement in FEV1 after repeat spirometric testing post-
administration of salbutamol.20
Ethical Considerations
Written informed consent was obtained from all care-
givers and written assent obtained from participants. Ethical
approval for the study was obtained from the Medical Research
Council of Zimbabwe, the Harare City Health Department
Ethics Committee, the Biomedical Research and Training
Institute Institutional Review Board, and the London School
of Hygiene and Tropical Medicine Ethics Committee.
RESULTS
During the study period, 9655 children were tested for
HIV of whom 449 (4.6%) tested HIV positive. An additional
21 participants were identiﬁed who had been diagnosed
before study commencement but had not engaged in care
and/or had not commenced ART. In total, 385 (86%)
participants were recruited into the study. The remainder
were not enrolled because of residence outside the study area
(n = 24, 5%), declined consent (n = 25, 5.5%), care sought
elsewhere (n = 34, 7.5%), and wrong age (n = 2, 0.4%). The
median age at diagnosis was 11 years (interquartile range
(IQR) 8–13), and 52% were female. Most participants were
infected through mother-to-child transmission based on
a history of maternal or natural sibling HIV or death, and
self-report of no sexual debut, blood transfusions or surgery,
and less than 2% of mothers of participants had received ART
for PMTCT. Although 78% of participants had attended
a PHC in the past 6 months and/or been previously
hospitalized, HIV testing had not been performed (Table 1).
More than half of participants rated their health in the
past 3 months as poor (Table 2). Chronic respiratory symptom
was frequent with 54% reporting cough of more than 1
month-duration and 16% reporting dyspnea. At rest, 12%
had oxygen saturations ,88% and a further 10% dropped
their oxygen saturations below 88% after exercise. Of the
238 participants who underwent spirometry and were able
to produce quality traces, 23 (10%) had obstructive lung
function defect with only 3 demonstrating reversibility
with salbutamol, and 43 (18%) had a reduced FVC.
Notably, despite 155 (40%) screening positive for TB on
the WHO screen, only 1 participant was found to have TB
on GeneXpert.
The median height-for-age, weight-for-age, and head
circumference–for-age z-scores were 21.2 (IQR 21.9 to
20.41), 21.1 (IQR 22.1 to 20.45), and 21.4 (IQR 22.4 to
20.66), respectively. In addition, 27% of girls and 13% of
boys were considered to have pubertal delay, and 24% of girls
aged 15 years had not experienced menarche. Of the 80
participants with WHO stage 4 disease, 66% were classiﬁed
as such based on stunting alone. Other chronic impairments
included hearing difﬁculties self-reported by 12%, visual
impairment by 6%, and speech impairment or gross motor
defects by 2%. Chronic skin disease was found in 25% of
participants on examination.
TABLE 1. Baseline Characteristics of Participants at HIV
Diagnosis (N = 385)
Characteristic N (%)
Demographic
Median (IQR) age, yrs 11 (8–13)
Female 199 (52)
Clinical history
Previous hospitalization 105 (27)
Attendance at PHC in past 6 mo 268 (70)
Previous TB treatment 18 (5)
Recurrent upper respiratory tract infection 107 (28)
Previous herpes zoster infection 41 (11)
HIV history
Mother or child received ART for PMTCT 5 (1)
Circumstances leading to HIV test
Attended PHC due to symptoms, ﬁrst HIV test 323 (84)
Previously tested but unengaged in care 19 (5)
Attended PHC for HIV testing 43 (11)
Likely HIV mode of acquisition
Mother-to-child transmission 366 (95)
Parenteral 6 (2)
Horizontal 12 (3)
Unknown 1 (0)
Median (IQR) CD4, cells/mm3* 375 (215–599)
CD4 count at diagnosis, cells/mm3
,200 88 (23)
200–499 162 (42)
$500 132 (35)
WHO stage
½ 229 (59)
¾ 156 (41)
*Data missing for 3 participants.
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The median CD4 count was 375 cells per cubic
millimeter (IQR 215–599) and 40% had WHO stage 3 or 4
HIV infection. Using a CD4 count threshold of 350 cells per
cubic millimeter and/or WHO stage 3/4 disease, 67% children
were eligible for ART, this ﬁgure increasing to 78% if the
threshold was changed to 500 cells per cubic millimeter.
Using logistic regression analysis adjusted for age and sex,
participant self-report of ill health in the past 3 months was
associated with a CD4 count ,350 cells per cubic millimeter
(adjusted odds ratio 1.89, 95% CI: 1.25 to 2.88) as was
having a chronic skin condition (adjusted odds ratio 1.65,
95% CI: 1.02 to 2.69). However, a CD4 count ,350 cells per
cubic millimeter or ,500 cells per cubic millimeter was not
associated with WHO stage, reduced FEV1 or FVC z-score or
growth parameters such as height-for-age, weight-for-age, or
head circumference z-scores (Table 3).
DISCUSSION
The main ﬁnding of this study was the heavy burden of
chronic morbidity among older children and adolescents at
time of HIV diagnosis. Consistent with other studies, a quarter
of participants had stunting and 23% had pubertal delay.25–27
Although catch-up growth can be achieved after initiation of
ART, children who begin treatment in later childhood are
typically unable to regain their height potential.28,29 In
addition, more than a third of participants had a head
circumference–for-age z-score less than 22, which could
partly be explained by suboptimal brain growth in early
childhood. Unlike the progressive encephalopathy, manifest
as failure to attain or loss of developmental milestones or
intellectual capacity and motor defects, that is typical in HIV-
infected infants and young children, gross motor defects and
speech impairment were rare among our participants with
slow-progressive disease. However, studies have reported
defects in seemingly asymptomatic HIV-infected children in
ﬁne motor function, memory, perceptual performance, quan-
titative abilities, and mental processing and language abili-
ties.30,31 These deﬁcits are subtle and are not easily identiﬁed
on routine questionnaire, and therefore, without formative
testing may have been an underrepresentation of degree of
morbidity in relation to higher functioning capacity in our
study. These ﬁndings have to be interpreted with caution;
however, as Western reference ranges for head circumference
were used because of a lack of normative data from African
children, and head circumference does vary by ethnic group.22
Chronic respiratory disease was common with cough,
hypoxia, reduced exercise tolerance, and obstructive lung
defects being the predominant features. Reversibility was
rare, making asthma unlikely. Other studies have also shown
a high prevalence of obstructive lung defects, with little or no
reversibility.32,33 A study which performed chest computed
tomography in adolescents with long-standing, vertically
acquired HIV infection showed that constrictive obliterative
bronchiolitis was the predominant cause of chronic lung
disease, with lymphoid interstitial pneumonitis (the most
commonly recognized cause of lung disease in HIV-infected
children) being a rare ﬁnding.12,34,35 Obliterative bronchiolitis
is a progressive, life-threatening condition and is well
recognized as sequelae of respiratory tract infections, which
were commonly reported by participants.36
A quarter of all participants had chronic dermatolog-
ical conditions. Although not life-threatening, these are
commonly recognized as stigmata of HIV infection, may
take long periods to resolve after ART and for some
conditions particularly planar warts, effective treatments
are not available.37,38
TABLE 2. Chronic Morbidity in Study Participants
Characteristic
No. Participants,
n (%)
Self-rated general health fair or poor in past 3 mo* 197 (52)
Fevers in the past month 162 (42)
Diarrhea 130 (34)
Loss of appetite 92 (24)
Oral candidiasis 43 (11)
Growth and sexual development
Height-for-age z-score ,22 91 (23)
Weight-for-age z-score ,22 106 (27)
Head circumference–for-age z-score ,22† 134 (35)
Body mass index–for-age z-score ,22 62 (16)
Delayed puberty‡ 18 (21)
Nonoccurrence of menarche by 15 yrs
of age (n = 17)§
4 (24)
Chronic respiratory disease
Chronic cough .1 mo 206 (54)
Medical Research Council Dyspnea score $2k 46 (16)
Digital clubbing 2 (0.5)
SpO2 ,88%¶ 45 (14)
Respiratory rate .30/min at rest# 14 (4)
$5% desaturation on exercise (n = 246) 24 (10)
FEV1 z-score, mean, SD** (n = 238) 20.73 (1.41)
FVC z-score, mean, SD** (n = 238) 20.63 (1.35)
FEF 25%–75% z-score, mean, SD** (n = 238) 20.19 (1.13)
Chronic skin disease
Any chronic skin condition 96 (25)
Molluscum contagiosum 37 (10)
Papular pruritic eruption 33 (9)
Planar warts 31 (8)
Verrucous warts 16 (4)
Other chronic conditions
Gingivitis/periodontitis 11 (3)
Visual impairment 22 (6)
Hearing impairment 46 (12)
Gross motor defects 2 (0.5)
Speech impairment 4 (1)
*Data missing for 3 participants.
†Data missing for 6 participants.
‡Deﬁned as females not reaching Tanner breast stage 2 by 13 years, males not
reaching Tanner testicular stage 2 by 14 years (denominator = 87).
§17 females in this age group.
kData missing for 94 participants—60 reason unknown, 18 missed respiratory
assessment, 14 too ill, 1 mental impairment, and 1 refused.
¶Data missing for 58 participants—18 reason unknown, 17 too ill, 16 missed
appointment, 5 equipment malfunction, 1 mental impairment, and 1 refused.
#Data missing for 60 participants—20 reason unknown, 17 too ill, 16 missed
appointment, 5 equipment malfunction, 1 mental impairment, and 1 refused.
**Data missing for 147 participants—91 uninterpretable trace, 9 missing data, 19
too ill, 11 missed appointment, 9 did not grasp technique, and 8 reason unknown.
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Importantly, we observed no association between CD4
count and WHO HIV disease stage, a ﬁnding also noted
previously.39 There was also no association between CD4
count and chronic conditions, including stunting and poor
lung function. Taken together, this implies that CD4 count
may not be an appropriate criterion for starting ART in older
children. This also has potential implications with respect to
timing of ART initiation. Based on the WHO 2013 HIV
treatment guidelines, 12% of participants would not have
been eligible for ART. Given the lack of evidence of the
mortality beneﬁt of immediate ART in older children and the
concern about drug toxicity and adherence, guidelines until
recently have recommended deferring ART in older children.8
Recent trials in adults have demonstrated that early initiation
of ART reduces the risk of AIDS and non-AIDS events,40,41
but these trials excluded older children and adolescents. Our
ﬁndings demonstrate that children with slow-progressing
disease may have preserved CD4 counts but do develop
chronic complications such as poor growth and chronic lung
disease. It is, thus, possible that immediate ART may also
prevent development of chronic complications in children. A
randomized controlled trial would deﬁnitively establish
whether immediate ART would prevent development or
progression of chronic complications, but this is not going
to be possible given the recent change in WHO guidelines
recommending immediate ART in all adults and children.
The scale-up of programs to PMTCT has resulted in
a substantial decline in the numbers of children infected with
HIV, but coverage remains suboptimal in many high burden
countries.42 The limited availability of HIV testing services
for children and the low rates of early infant diagnosis mean
that for many infected infants, HIV diagnosis occurs in late
childhood or adolescence after many years of ill health.43 In
this study, 78% of participants had previous contact with
health facilities, including 27% having been hospitalized, but
had not had HIV testing. Despite recommendations that PITC
should be offered as standard in health facilities in HIV high
prevalence settings, in practice, HIV testing is often prompted
only after presentation with typical HIV-related symptoms.44
Children with slow-progressing disease may take years before
they develop the well-recognized HIV indicator conditions
that prompt an offer of HIV testing, by which time they
develop chronic complications and organ damage which may
not be reversible with ART once established.
To our knowledge, this is the ﬁrst study to report the
prevalence of morbidity at HIV diagnosis in children and
adolescents with long-standing HIV infection. Most children
were vertically infected, implying living with HIV infection
for up to 15 years without previous treatment. Participants
were diagnosed after optimized PITC of attendees regardless
of cause of presentation, with 80% of all attendees with
previously unknown HIV status undergoing HIV testing (data
not shown). The study was based in primary care facilities
and therefore was not biased toward sicker children. We
acknowledge several limitations. There was no HIV-
uninfected or an HIV-treated comparison group in our study.
Vision, hearing, neurocognitive, and musculoskeletal func-
tion were not formally assessed but relied on self-report. Lung
function assessment was not performed in 5% of participants.
This was partly due to logistic reasons as respiratory
assessment could not be performed at the initial assessment
necessitating a second appointment within 2 weeks which
some participants did not attend. Spirometric traces could not
be interpreted in 100 (26%) participants. In addition, 19 (5%)
participants were too ill to perform both spirometry and/or
ISWT, which may have led to an underestimation of degree of
lung disease present among the participants. Local reference
ranges for lung function, puberty, and head circumference are
not available. British reference ranges were used for height
and weight z-score calculations because of a lack of WHO
TABLE 3. Association of Clinical Conditions With CD4 Count at Study Enrollment
CD4 Count ,350 cells/mm3*
(N = 177), n (%)
CD4 Count ,350 cells/mm3
aORk (95% CI)
CD4 Count ,500 cells/mm3
(N = 250), n (%)
CD4 Count,500 cells/mm3
aOR (95% CI)
WHO stage ¾ 77 (44) 1.25 (0.82 to 1.91) 107 (43) 1.33 (0.84 to 2.10)
Self-rated general health fair/
poor in past 3 mo†
106 (60) 1.89 (1.25 to 2.88) 137 (55) 1.49 (0.95 to 2.32)
Chronic skin condition 55 (31) 1.65 (1.02 to 2.69) 72 (29) 1.61 (0.93 to 2.79)
Height-for-age z-score ,22 43 (24) 0.90 (0.55 to 1.48) 65 (26) 1.27 (0.73 to 2.19)
Weight-for-age z-score ,22 56 (32) 1.24 (0.77 to 1.99) 78 (31) 1.50 (0.88 to 2.56)
Head circumference–for-age
z-score ,22‡
57 (32) 0.98 (0.63 to 1.54) 83 (33) 1.12 (0.70 to 1.82)
Pubertal delay 9 (5) 0.68 (0.25 to 1.84) 15 (6) 1.75 (0.47 to 6.50)
Visual impairment 12 (7) 1.32 (0.54 to 3.23) 18 (7) 2.43 (0.77 to 7.66)
Hearing impairment 25 (14) 1.41 (0.75 to 2.66) 33 (13) 1.29 (0.64 to 2.61)
FEV1 z-score ,21.64§ 32 (18) 1.39 (0.76 to 2.54) 42 (17) 1.55 (0.78 to 3.09)
FVC z-score ,21.64§ 25 (14) 1.41 (0.72 to 2.76) 30 (12) 1.09 (0.52 to 2.28)
*Data missing for 3 participants—laboratory error.
†Data missing for 3 participants.
‡Data missing for 6 participants.
§Data missing for 147 participants—91 uninterpretable trace, 9 missing data, 19 too ill to perform spirometry, 11 missed respiratory assessment, 9 did not grasp technique, and 8
reason unknown.
kaOR (adjusted odds ratio) for age and sex.
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weight-for-age reference ranges for children over 9 years of
age, which may not be appropriate for an African population.
Our study shows a substantial burden of chronic
morbidity among HIV-infected children diagnosed in later
childhood, even among those with preserved CD4 counts.
Recognition of this burden is needed to stimulate earlier
diagnosis and improve access to HIV care for this age group.
There is a pressing need to strengthen PITC and potentially
provide other more effective services for HIV testing in this
age group, and for timely institution of ART. Current
recommendations of deferred ART in children may put them
at risk of developing chronic complications. The recent WHO
guidelines recommending treatment of all HIV-infected
individuals regardless of age and disease stage may reduce
the risk of development of chronic complications. Studies
investigating the impact of immediate ART on AIDS and
non-AIDS events in children and the pathogenesis of chronic
complications will inform development of optimum care
provision for HIV-infected children.
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